The Clinical Value of COVID in the First Interim Analysis

I think with sort of again within the frame that we assessed this appears to be safe. If you move to either direction in your clinical work I think you should consider this a lot of post-buying being more restricted than we were and also being more liberal than we were. And Tila mentioned that the clinician behavior appear to change around the time of the first interim analysis when people start giving less fluid out of interestWere there any primary outcome signals from the first interim study which were instructive or there were the different in direction from the final results? We don't have a primary outcome date of those analysis. So in the first interimAnalysis only protocol adherence was assessed so we don't